Carfilzomib kills cancer cells by permanently disabling the proteasome, a molecular machine inside every cell that breaks down damaged or unneeded proteins. By locking onto the proteasome’s active sites with an irreversible chemical bond, carfilzomib causes toxic proteins to pile up inside myeloma cells until they self-destruct. That permanent grip on the target is the key difference between carfilzomib and its predecessor bortezomib, and it shapes everything from the drug’s effectiveness to its side-effect profile.
How Carfilzomib Binds the Proteasome
Every cell contains barrel-shaped protein complexes called proteasomes whose job is to chew up proteins tagged for disposal. The core of the proteasome, known as the 20S particle, has several active sites that each specialize in cutting proteins at different types of amino acid bonds. Carfilzomib belongs to a chemical class called epoxyketones, and its reactive end reacts with a specific amino acid (threonine) at the entrance to these active sites. When carfilzomib meets that threonine, it forms a two-point covalent attachment, creating a small ring structure called a morpholino ring that locks the drug permanently in place.1Structure. Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib Because this bond is covalent and irreversible, the proteasome subunit that carfilzomib attaches to is shut down for the life of that protein complex. The cell has to build entirely new proteasomes to recover its protein-recycling capacity.2PubMed Central. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Bortezomib, the first proteasome inhibitor approved for myeloma, uses a boronic acid group instead of an epoxyketone. That boronic acid bond is reversible: bortezomib latches on, then eventually lets go, and the proteasome can resume working. The irreversible nature of carfilzomib’s binding means it achieves more sustained proteasome blockade, which is part of why it can work in patients whose myeloma has already stopped responding to bortezomib.3PubMed Central. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Which Proteasome Subunits It Targets
The 20S proteasome contains three pairs of catalytic subunits, each named for the type of protein bond it prefers to cut. Carfilzomib’s primary target is the chymotrypsin-like subunit, called β5 in the standard (“constitutive”) proteasome and LMP7 in the immunoproteasome, a variant found mainly in immune cells.4PubMed. Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs) Carfilzomib potently and selectively blocks the chymotrypsin-like activity in both versions of the proteasome.5Blood. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
That selectivity is not absolute, though. Studies of patients receiving carfilzomib showed that at standard doses of 15 to 20 mg/m², the drug blocked more than 80% of the chymotrypsin-like sites (β5 and LMP7).6Blood. Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients At higher doses around 45 mg/m², occupancy climbed at additional subunits, particularly MECL1 and LMP2 (two immunoproteasome-specific sites), in a dose-dependent fashion. The one subunit that carfilzomib largely spares is β1, the caspase-like site of the constitutive proteasome.7PubMed Central. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
Why does this subunit profile matter? Crystal structure work on the human 20S proteasome revealed that specific pockets near the chymotrypsin-like active sites (referred to as S3 and S4 binding pockets) are the main reason carfilzomib preferentially slides into those sites rather than others. Slight amino acid differences between the constitutive and immunoproteasome versions of this subunit also explain why carfilzomib has a modest preference for the constitutive form.8Structure. Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib In practical terms, hitting multiple subunits at clinically achievable doses likely contributes to the drug’s potency, and the correlation between broader subunit blockade and clinical response has been confirmed in patient samples.9PubMed Central. Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
What Happens Inside Cancer Cells When the Proteasome Stalls
When the proteasome cannot do its job, several things go wrong inside a cancer cell simultaneously. The most immediate consequence is a buildup of misfolded and damaged proteins. Myeloma cells are essentially factories that churn out enormous quantities of antibody protein, and they depend heavily on the proteasome to clear defective copies. Blocking that disposal system creates a kind of toxic traffic jam.
One of the most important downstream effects involves NF-κB, a signaling molecule that myeloma cells rely on to stay alive. Under normal conditions, NF-κB is kept inactive by a partner protein called IκB. When the cell wants to activate NF-κB, it tags IκB for destruction by the proteasome. With the proteasome blocked, IκB stays intact and keeps NF-κB switched off. Research in mantle cell lymphoma cells confirmed that carfilzomib completely blocks the phosphorylation step that would normally mark IκB for degradation, shutting down NF-κB signaling and triggering programmed cell death.10PubMed. Carfilzomib Inhibits Constitutive NF-κB Activation in Mantle Cell Lymphoma B Cells and Leads to the Induction of Apoptosis
The actual death sequence in myeloma cells involves multiple coordinated events. Preclinical studies showed that carfilzomib activates stress-response enzymes (c-Jun N-terminal kinase), collapses the energy-producing membranes inside mitochondria, and triggers both the intrinsic and extrinsic branches of the caspase cascade, the cell’s built-in demolition machinery.11PubMed Central. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma This multi-pronged assault is one reason carfilzomib can still kill cells that have developed escape routes against single death pathways.
There is a twist, however. While proteasome blockade pushes cells toward death, it also triggers a survival reflex. The accumulation of unfolded proteins activates what is called the unfolded protein response, which in turn ramps up autophagy, a housekeeping process where the cell digests its own damaged components to stay alive. Research showed that carfilzomib-induced autophagy is partially dependent on a stress-response protein called ATF4, and that this autophagy actually promotes cancer cell survival rather than contributing to cell death.12Taylor & Francis Online / Autophagy. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4 This survival-autophagy response is a built-in limitation of proteasome inhibitor therapy and a target for combination strategies.
Effects on Bone in Myeloma
Multiple myeloma does not just grow in the bone marrow; it actively destroys the surrounding bone. Myeloma cells stimulate bone-eating cells (osteoclasts) and suppress bone-building cells (osteoblasts), leading to painful fractures and lesions. Carfilzomib appears to counteract both sides of this imbalance. At concentrations achievable in patients, carfilzomib directly inhibited osteoclast formation and bone breakdown in lab models while simultaneously enhancing the activity of osteoblasts and promoting new bone mineral deposition. In mice without tumors, the drug increased the volume of spongy bone, decreased bone breakdown, and enhanced new bone formation.13PubMed Central. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
The mechanism behind this bone-protective effect circles back to NF-κB. Osteoclasts need NF-κB signaling to mature, and carfilzomib blocks the degradation of IκB in osteoclasts just as it does in cancer cells. One study demonstrated that carfilzomib suppresses hormone-induced osteoclast differentiation and bone resorption by preventing NF-κB activation in these cells.14Journal of Biological Chemistry. Carfilzomib suppresses parathyroid hormone-induced osteoclast differentiation and bone resorption by targeting both osteoblasts and osteoclasts This dual action on both cancer cells and the bone environment is a meaningful advantage in myeloma, where skeletal damage is a major source of suffering.
Why Carfilzomib Causes Less Nerve Damage Than Bortezomib
Peripheral neuropathy, the painful tingling and numbness in hands and feet, is one of the most dreaded side effects of bortezomib. Carfilzomib causes far less of it, and the reason appears to be the drug’s greater selectivity for the proteasome. Proteomic studies comparing nerve-cell responses to the two drugs found that bortezomib produced more protein damage markers (specifically, higher levels of protein carbonyls and ubiquitinated proteins) than carfilzomib did, even though both drugs inhibited the proteasome to a similar degree. The interpretation is that bortezomib’s boronic acid warhead reacts with proteins beyond the proteasome, while carfilzomib’s epoxyketone group is more selective and causes less collateral damage to non-target proteins in nerve tissue.15Scientific Reports. Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
This selectivity advantage is a direct result of the binding chemistry described earlier. The two-point morpholino ring that carfilzomib forms is highly specific to the threonine residue at proteasome active sites, a feature that is essentially unique to the proteasome among human enzymes. Bortezomib’s boronic acid, by contrast, can interact with serine residues found in many other cellular proteins, and those off-target reactions appear to be what injures nerve cells.
The Cardiovascular Trade-Off
If carfilzomib’s advantage is sparing nerves, its disadvantage is a higher rate of cardiovascular problems. Heart failure, high blood pressure, and cardiac events are more common with carfilzomib than with bortezomib. Research into why this happens has pointed to a different set of molecular pathways. Carfilzomib appears to disrupt signaling through the Akt/eNOS axis in heart cells, which normally helps maintain blood vessel function and protect against inflammation. At the same time, carfilzomib increases levels of iNOS, an enzyme linked to inflammatory damage. The drug also reduces activation of AMPKα, an energy sensor in heart cells, and inhibition of both AMPKα and Akt leads to decreased phosphorylation of FOXO1, a protein whose activation can push cells toward self-destruction.16Blood. Comparison of Proteasome Inhibitors-Induced Cardiotoxicity (carfilzomib vs. bortezomib): Insights into the Molecular Mechanisms
There is also an indirect vascular effect. By blocking proteasome function in endothelial cells (the cells lining blood vessels), carfilzomib inhibits the NF-κB pathway in those cells too, which in turn reduces production of VEGF, a growth factor that helps maintain healthy blood vessel walls. Lower VEGF levels decrease the production of complement regulatory proteins in the kidney, potentially leaving the kidney’s small blood vessels vulnerable to complement-mediated damage. This chain of events has been proposed as a mechanism behind the rare but serious complication of thrombotic microangiopathy, a condition in which tiny blood clots form in small vessels throughout the body.17PubMed Central. Carfilzomib-Induced Thrombotic Microangiopathy: Focus on Pathogenesis The irony is that the very same NF-κB blockade that makes carfilzomib effective against myeloma cells also disrupts protective signaling in the heart and kidneys.
How the Body Processes Carfilzomib
Carfilzomib has an unusual metabolic profile that influences both its dosing and its drug-interaction potential. The drug is cleared from the bloodstream very rapidly, with a short half-life measured in minutes rather than hours. Unlike many cancer drugs, it is not primarily broken down by liver enzymes from the cytochrome P450 family. Instead, carfilzomib is degraded mainly outside the liver, through two reactions: peptidase enzymes snip apart its peptide backbone, and water-based chemistry opens up the reactive epoxide group (epoxide hydrolysis).18Drug Metabolism and Disposition. Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib Because carfilzomib largely bypasses the liver’s main drug-processing enzymes, it has a relatively low potential for drug-drug interactions compared to many other cancer therapies. This extrahepatic clearance pattern has been consistent across both animal models and human patients.19Drug Metabolism and Disposition. Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib
This rapid clearance is actually a feature rather than a bug. Carfilzomib only needs a brief window of exposure to form its irreversible bond with the proteasome. Once the bond is made, it does not matter that the free drug disappears quickly from the blood. The proteasome remains inhibited until the cell builds a replacement. This pharmacokinetic quirk explains why carfilzomib is given as a short intravenous infusion rather than as an oral pill or a continuous drip.
How Myeloma Cells Develop Resistance
Resistance to carfilzomib is a growing clinical concern. One of the best-characterized escape routes involves a drug pump called ABCB1 (also known as P-glycoprotein or MDR1). Myeloma cells that survive prolonged carfilzomib exposure frequently crank up production of ABCB1 on their surface, which physically pumps carfilzomib out of the cell before it can reach the proteasome. Lab studies showed that eliminating the ABCB1 gene using gene-editing tools restored carfilzomib sensitivity, reducing the concentration needed to kill resistant cells by roughly eightfold.20PubMed Central. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma A separate set of experiments confirmed the same principle: blocking ABCB1 with a chemical inhibitor called reversin 121 brought drug-resistant cells back to nearly the same sensitivity as their original, untreated counterparts.21PubMed Central. Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1
Interestingly, bortezomib is not a good substrate for the ABCB1 pump, meaning this particular resistance mechanism is specific to carfilzomib.22PubMed Central. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma This difference matters clinically: a patient whose myeloma becomes resistant to carfilzomib through ABCB1 upregulation might still respond to bortezomib, and vice versa.
Drug pumps are not the only resistance strategy. Bone marrow plasma cells that survived carfilzomib treatment in transplant-desensitization studies showed increased expression of the immunoproteasome, the immune-cell variant of the proteasome, along with its activator complex PA28. This suggests that cells can compensate for proteasome inhibition by assembling alternative proteasome forms that may be partially resistant to carfilzomib’s effects.23PubMed Central. Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells The picture of resistance is still evolving, with multiple non-proteasomal signaling changes also suspected to contribute, but the field is far from a complete map.
Why Combinations Strengthen the Effect
Carfilzomib is rarely used alone in clinical practice. Combining it with other drug classes amplifies its anti-myeloma activity through complementary mechanisms. Immunomodulatory drugs (like lenalidomide) stimulate the immune system to attack myeloma cells from a different angle. Glucocorticoids such as dexamethasone kill myeloma cells through their own receptor-mediated pathways and reduce inflammation that supports tumor growth. Histone deacetylase inhibitors alter gene expression patterns in ways that can make myeloma cells more sensitive to proteasome blockade.24PubMed. The emerging role of carfilzomib combination therapy in the management of multiple myeloma
The rationale for combinations also relates to the survival autophagy described earlier. Since cancer cells can partially protect themselves from proteasome inhibition by ramping up autophagy, adding a second drug that blocks autophagy or attacks a separate survival pathway can close that escape hatch. The pro-survival autophagy triggered by carfilzomib provides a concrete biological reason to pursue multi-drug regimens rather than relying on carfilzomib as a single agent. Clinical trials have tested carfilzomib alongside immunomodulators, alkylating agents, and other targeted therapies, and multi-drug approaches now represent the standard way the drug is deployed.
The ongoing challenge is balancing efficacy against toxicity. Adding more drugs to carfilzomib regimens improves response rates but can compound side effects, particularly the cardiovascular risks already inherent to carfilzomib. Clinicians weigh a patient’s cardiac history, kidney function, and prior treatment exposure when choosing which combination is most appropriate, and dose adjustments during treatment are common. Understanding the molecular mechanisms behind both the drug’s anticancer effects and its organ toxicities helps explain why these clinical decisions are rarely straightforward.